1、 SEVER P S, DAHL F B, POULTER, et al. Prevention of coronary and stroke events with atorvastatin In hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre Randomized controlled trial[J]. The Lancet,2003,361(9364): 1149-1158. SEVER P S, DAHL F B, POULTER, et al. Prevention of coronary and stroke events with atorvastatin In hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre Randomized controlled trial[J]. The Lancet,2003,361(9364): 1149-1158.
2、 LAW M R, MORRIS J K, WALD N J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies[J]. Bmj, 2009, 19(338): b1665. LAW M R, MORRIS J K, WALD N J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies[J]. Bmj, 2009, 19(338): b1665.
3、 赵声超, 赵鹏, 郭亚伟,等.深圳市社区40岁以上人群脑卒中危险因素现况[J]. 现代医院, 2017,17(6):844-848. 赵声超, 赵鹏, 郭亚伟,等.深圳市社区40岁以上人群脑卒中危险因素现况[J]. 现代医院, 2017,17(6):844-848.
4、 DICKINSON H O, MASON J M, NICOLSON D J, et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials[J]. J Hypertens, 2006, 24(2): 215-233. DICKINSON H O, MASON J M, NICOLSON D J, et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials[J]. J Hypertens, 2006, 24(2): 215-233.
5、 EZZATI M, LOPEZ A D, RODGERS A, et al. Selected major risk factors and global and regional burden of disease[J]. The Lancet, 2002, 360(9343): 1347-1360. EZZATI M, LOPEZ A D, RODGERS A, et al. Selected major risk factors and global and regional burden of disease[J]. The Lancet, 2002, 360(9343): 1347-1360.
6、 刘力生. 中国高血压防治指南2010[J]. 中华高血压杂志, 2011,19 (8): 701-743. 刘力生. 中国高血压防治指南2010[J]. 中华高血压杂志, 2011,19 (8): 701-743.
7、 郭淑霞, 张景玉, 张翼华, 等. 新疆哈萨克族与汉族高血压流行病学特点比较与分析[J]. 石河子大学学报(自然科学版), 2008, 26(5): 538-540. 郭淑霞, 张景玉, 张翼华, 等. 新疆哈萨克族与汉族高血压流行病学特点比较与分析[J]. 石河子大学学报(自然科学版), 2008, 26(5): 538-540.
8、 赵蕾,王坤, 郭艳英, 等. 新疆博尔塔拉蒙古自治州蒙、哈、维、汉4民族30岁以上高血压及部分有关危险因素调查[J]. 高血压杂志, 2006,14 (3): 214-218. 赵蕾,王坤, 郭艳英, 等. 新疆博尔塔拉蒙古自治州蒙、哈、维、汉4民族30岁以上高血压及部分有关危险因素调查[J]. 高血压杂志, 2006,14 (3): 214-218.
9、 王红梅, 李南方, 姚晓光, 等. 新疆阜康牧区哈萨克族人群高血压的群体流行病学研究[J]. 中华高血压杂志, 2010, 18(10): 960-964. 王红梅, 李南方, 姚晓光, 等. 新疆阜康牧区哈萨克族人群高血压的群体流行病学研究[J]. 中华高血压杂志, 2010, 18(10): 960-964.
10、 赖艳娴, 邓聪, 郭宝云, 等.维族原发性高血压人群ACE多态性及水平相关性分析[J].广州医药,2015,43(4):20-22. 赖艳娴, 邓聪, 郭宝云, 等.维族原发性高血压人群ACE多态性及水平相关性分析[J].广州医药,2015,43(4):20-22.
